Cytochrome P450 monooxygenases often determine the clearance of candidate drugs limiting their therapeutic efficacy. These enzymes can also be sources of off-target toxicity. Our long term objective is to understand the structural determinants of substrate recognition by P450 enzymes. Collectively and individually the human drug metabolizing P450s can metabolize structurally diverse range of substrates, and this is likely to reflect in part the flexibility of each enzyme and structural adaptations for substrate binding. This underscores the necessity to determine multiple structures of individual enzymes in complex with structurally dissimilar drugs to understand the contribution of conformational flexibility to drug binding. Specific changes in the active site architectures of P450s 1A2, 2C19 and 3A5 induced by interaction with chemically diverse substrates or inhibitors will be identified to delineate the range of adaptive changes that can occur for each enzyme. Additionally, the active site topologies of P450s 2J2, 3A7 and representative family 4A enzymes will also be determined to identify structural characteristics that control the important functional contribution made by these enzymes to drug metabolism and to the clearance of xenobiotics and excess endogenous compounds. Collectively, these studies will address significant gaps in our knowledge of P450 structure as it relates to function, and provide important information and tools for lead compound optimization in drug development to improve efficacy and reduce risks of metabolic drug-drug interactions.
These studies will provide new information to guide drug design in order to improve efficacy and reduce undesirable off-target effects resulting from cytochrome P450 mediated drug metabolism. This will benefit a wide range of therapeutic areas targeted for drug development.
|Jennings, Gareth K; Hsu, Mei-Hui; Shock, Lisa S et al. (2018) Noncovalent interactions dominate dynamic heme distortion in cytochrome P450 4B1. J Biol Chem 293:11433-11446|
|Hsu, Mei-Hui; Savas, Uzen; Johnson, Eric F (2018) The X-Ray Crystal Structure of the Human Mono-Oxygenase Cytochrome P450 3A5-Ritonavir Complex Reveals Active Site Differences between P450s 3A4 and 3A5. Mol Pharmacol 93:14-24|
|Butler, Christopher R; Ogilvie, Kevin; Martinez-Alsina, Luis et al. (2017) Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality. J Med Chem 60:386-402|
|Hsu, Mei-Hui; Baer, Brian R; Rettie, Allan E et al. (2017) The Crystal Structure of Cytochrome P450 4B1 (CYP4B1) Monooxygenase Complexed with Octane Discloses Several Structural Adaptations for ?-Hydroxylation. J Biol Chem 292:5610-5621|
|Liu, Renhe; Lyu, Xiaoxuan; Batt, Sarah M et al. (2017) Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes. Angew Chem Int Ed Engl 56:13011-13015|
|Brodney, Michael A; Beck, Elizabeth M; Butler, Christopher R et al. (2015) Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors. J Med Chem 58:3223-52|
|Wang, An; Stout, C David; Zhang, Qinghai et al. (2015) Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding. J Biol Chem 290:5092-104|
|Johnson, Eric F; Connick, J Patrick; Reed, James R et al. (2014) Correlating structure and function of drug-metabolizing enzymes: progress and ongoing challenges. Drug Metab Dispos 42:9-22|
|Johnson, Eric F; Stout, C David (2013) Structural diversity of eukaryotic membrane cytochrome p450s. J Biol Chem 288:17082-90|
|Reynald, R Leila; Sansen, Stefaan; Stout, C David et al. (2012) Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19. J Biol Chem 287:44581-91|
Showing the most recent 10 out of 80 publications